Drugs and patents in ATC class L01BB

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
MERCAPTOPURINE	mercaptopurine
PURIXAN	mercaptopurine
PURINETHOL	mercaptopurine
CLADRIBINE	cladribine
>Tradename	>Generic Name

Last updated: June 27, 2026

ATC L01BB (“Purine analogues”) groups multiple oncology drugs with distinct origin classes: small-molecule nucleoside analogues (largely off-patent in many jurisdictions), prodrugs, and select newer agents with branded IP. The market is fragmented across indications (ALL, CML, NHL, leukemias, maintenance), with patent estates dominated by: (i) composition-of-matter and prodrug/derivative claims, (ii) formulation/solid-state and manufacturing process claims, and (iii) method-of-use claims for specific dosing schedules.

The patent landscape is not uniform across L01BB. The most defensible IP pockets typically sit with newer, line-extended compounds (including prodrugs and targeted combinations) and with formulation/process patents around oral solid dosage forms. In contrast, older nucleoside analogues that anchor portions of the class often show broad generic entry that tracks patent expiry of the core active ingredient, with remaining exclusivity shifting to secondary patents that survive later litigation or regulatory exclusivity.

Which purine analogues are in ATC L01BB and what drives their market share?

ATC L01BB is an oncology chemistry bucket for “purine analogues.” It includes nucleoside and nucleobase analogues used in hematologic malignancies and some solid-tumor regimens, spanning both chemotherapy and targeted-adjacent regimens.

What is the commercial demand profile across L01BB?

Demand drivers are primarily:

Disease incidence and treatment intensity in acute and chronic leukemias.
Line-of-therapy mix (induction, consolidation, maintenance).
Oral versus IV administration preferences and health-system formularies.
Combination regimen selection (where method-of-use patents can matter).

Which L01BB products tend to attract the strongest patent estates?

Strongest patent estates typically correlate with:

Newer oral purine analogues and prodrugs.
Drugs with meaningful differentiation by formulation, dosing, or safety-tolerability improvements that generated later patent filings.
Products with ongoing label evolution that supports new method-of-use claims.

How does the class compare to other ATC oncology categories?

Relative to broader nucleoside/nucleotide classes, L01BB typically sees:

More aggressive lifecycle management through formulations for oral regimens.
More frequent method-of-use claim activity tied to maintenance dosing and schedule refinements.

What patents protect purine analogues in ATC L01BB: composition, formulation, process, and method-of-use?

Purine analogues typically have patent coverage distributed across four claim families. The practical question for licensing and generic entry is not “do patents exist,” but “which claim type still blocks regulatory approval or commercial manufacture.”

Composition-of-matter: active ingredient and prodrug derivatives

For small-molecule nucleoside analogues and prodrugs, composition-of-matter coverage usually provides the earliest and strongest exclusion. As the basic scaffold ages, secondary patents can remain but typically narrow.

Common scope patterns:

Base nucleoside analogue and specific stereochemistry.
Prodrug forms (esters, phosphoramidate-like motifs, or solubilizing derivatives).
Specific substitution patterns that preserve therapeutic activity.

Formulation patents: oral solids, IV stability, and excipient systems

Formulation patents matter most when:

Oral solid dosage forms have specific dissolution profiles or polymorph/particle-size controls.
IV products require stabilization (pH, chelators, surfactants) and manufacturing controls.

Manufacturing process patents

Process claims can block manufacture even if composition claims are weak, particularly where:

Specific crystallization steps and control of residual solvents are claimed.
Scale-up parameters are claim-relevant.

Method-of-use and dosing regimen patents

Method-of-use coverage can remain after the active ingredient’s composition expiry by tying exclusivity to:

Maintenance schedules.
Combination regimens with specific partner agents.
Patient subpopulations or biomarker-defined approaches.

How strong are method-of-use patents in practice?

Method-of-use enforceability depends on:

Claim drafting (steps clearly defined and non-abstract).
Proof of use in the jurisdiction (prescribing practices and label).
Litigation history and court interpretation of “use” claims.

When does exclusivity for L01BB purine analogues end: patent expiry versus regulatory exclusivity?

Exclusivity is not one date. For most L01BB products, market lock-up comes from a blend of:

Primary composition-of-matter expiry.
Secondary patent expiry (formulations, processes, methods).
Regulatory exclusivities that can extend practical entry even after core patent expiry.

What timeline typically governs generic entry in L01BB?

A typical sequence looks like:

Early product launch: initial composition patent(s) and related claims.
Post-launch lifecycle: formulation and process improvements.
Label expansions: method-of-use filings.
Generic planning window: OGD (Orange Book) or equivalent territory mapping.
FDA/EMA regulatory submissions timed to patent landscape.

How do you distinguish patent expiry from market entry in L01BB?

Even when primary patents expire, generic entry often depends on:

Whether secondary patents remain listed for the specific formulation strength.
Whether Paragraph IV-type challenges have occurred and succeeded.
Whether settlements delayed launch or narrowed launch-to-territory.

What patent estate risks exist for generic entry of purine analogues in ATC L01BB?

Generic entry risk is driven by how many active, enforceable patents are listed and whether generics can design around them.

How many patents typically cover L01BB actives at launch and after?

Across complex oncology products, the number of listed patents can be high, but the number that matters at launch is smaller:

Only patents listed for the relevant drug product (strength/form) are immediately relevant for FDA submissions.
Process and formulation patents can be “design-aroundable,” but only with credible chemistry and stability evidence.

Which IP barriers delay generic launch?

Common barriers:

Listed formulation patents tied to a specific solid-state form or specific excipient profile.
Listed method-of-use patents that block approval for a use but not necessarily the entire drug.
Injunction risk from continuing litigation at multiple circuit/venue levels.

Where do generic applicants often succeed?

Generic applicants typically succeed when:

The remaining patents are weak or design-aroundable.
Settlement agreements allow “at-risk” launch dates.
The labeling carve-out strategy is available.

How many Paragraph IV challenges have been filed for ATC L01BB purine analogues and who is involved?

Paragraph IV activity is product-specific and is best assessed by drug-level Orange Book mapping. Without drug-specific identifiers and Orange Book listing data in the prompt, it is not possible to enumerate Paragraph IV filings reliably across the entire ATC L01BB class.

What is the Orange Book status of ATC L01BB purine analogues (listed patents and exclusivity entries)?

Orange Book status also requires drug-level identification and listing extraction. Without active ingredient names and strength/form identifiers, a complete, accurate Orange Book table for “ATC L01BB purine analogues” cannot be produced.

Which companies are challenging patents or defending exclusivity for L01BB purine analogues?

Patent enforcement and defense in oncology nucleoside analogues involves:

Originator brands and assignees defending composition/formulation/process claims.
Generic manufacturers pursuing Paragraph IV challenges.
Litigation involving US courts for FDA approvals, and EMA/territory enforcement via local courts.

A defensible competitor map requires specific active ingredients and current assignees that are not provided in the prompt.

What patent litigation affects ATC L01BB purine analogues: settlements, injunctions, and trial outcomes?

Litigation outcomes are highly dependent on:

Specific patent numbers and claim construction.
Whether the litigation resulted in a settlement with delayed entry.
Whether an injunction attached to the specific NDC/strength/form.

Without drug-level inputs, listing “what litigation affects” the entire ATC L01BB class would be inaccurate.

How do biosimilar risks apply to ATC L01BB purine analogues?

Biosimilar risk is generally low for ATC L01BB because the class is dominated by small molecules, not biologics. Where L01BB products are nucleoside analogues, they are not subject to the BPCIA biosimilar pathway.

How does the patent landscape for purine analogues compare across oral versus IV purine analogues?

Oral formulations

Oral purine analogues tend to have:

Stronger solid-state/formulation patents (polymorphs, particle size, dissolution).
More secondary patent activity that can be listed per strength and dosage form.

Generic risk tends to concentrate around:

Bioequivalence and formulation similarity that still avoids claimed properties.
Stability and dissolution specs required to establish equivalence without infringing.

IV/infusion formulations

IV products tend to face:

Process and stability patents.
Fewer solid-state claims, more claims around formulation composition and manufacturing controls.

Generic risk tends to concentrate around:

Recreating stabilized compositions and meeting sterility and shelf-life without infringing composition/process claims.

What formulations are protected by ATC L01BB purine analogues patents?

Formulation IP generally targets:

Oral solid dosage (immediate-release versus extended-release where applicable).
Specific excipient compositions and ratios.
Solid-state forms (polymorphs or hydrate forms) and manufacturing routes.
IV solution stability under labeled storage and infusion conditions.

A formulation-by-formulation protection map requires named drug products.

What generic entry scenarios exist for purine analogues in ATC L01BB?

Entry scenarios that recur in oncology small molecules include:

“Full generic” launch: matching label and overcoming relevant patents via design-around or expiry.
“Carve-out” label strategy: launch for indications not covered by method-of-use patents.
“Delayed launch via settlement”: entry shifted by settlement terms.
“At-risk launch”: entry before resolution at the applicant’s financial risk.

The correct selection is drug-dependent and hinges on Orange Book listed patents.

Revenue exposure: how much of ATC oncology spending sits in ATC L01BB purine analogues?

Revenue exposure cannot be quantified from the prompt without enumerating the specific L01BB products and their global and territory sales. The class is broad and includes agents with materially different revenue footprints.

Key Takeaways

ATC L01BB purine analogues is a mixed-small-molecule oncology class where patent estates cluster in composition-of-matter, formulation/solid-state, manufacturing process, and method-of-use/dosing regimen claims.
Exclusivity and generic entry timing are governed by the number and enforceability of listed patents per NDC strength/form, not by the class label.
Biosimilar risk is generally not applicable across L01BB because the class is dominated by small molecules rather than biologics.
A litigation and Paragraph IV map must be constructed drug-by-drug using active ingredient names, NDCs, and Orange Book listings; class-level aggregation is not decision-grade.

FAQs

How do you map ATC L01BB patent risk to specific FDA NDC strengths?
Which types of secondary patents (formulation vs method-of-use) most often block generic launches for purine analogues?
What settlement patterns commonly delay generic entry for oncology small molecules in purine analogue classes?
How should investors assess remaining patent value after core composition-of-matter expiry in L01BB?
When does a design-around strategy work for purine analogue formulations without triggering infringement?

Drugs in ATC Class L01BB

Drugs in ATC Class: L01BB - Purine analogues

Market dynamics and patent landscape for ATC Class L01BB (Purine analogues): who owns IP, when exclusivity expires, and where generics/biosimilars face barriers